Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Electrovaya Q1 FY2026 Earnings Call - Revenue up ~40%, profitable quarter while Jamestown and new products set the next test
Electrovaya kicked off fiscal 2026 with a markedly stronger quarter: revenue of $15.5 million, a near 40% year-over-year jump, improved gross margins and the fourth consecutive profitable quarter. Man...
- Top-line: Q1 revenue was $15.5 million, up 39% from $11.1 million a year earlier, despite Q1 seasonality in material handling.
- Profitability: Gross margin improved to 32.9% (up ~240 bps), operating profit was $1.4 million versus a prior-year operating loss, and net income was about $1 million, marking the fourth consecutive profitable quarter.
- EBITDA and cash flow: Adjusted EBITDA was $2.0 million (13% of revenue), up from $0.5 million a year ago. The company generated $1.7 million of cash from operations versus cash used of $0.3 million in the prior year.
- +12 more takeaways
Callaway Golf Company Fourth Quarter 2025 Earnings Call - Return to Pure-Play Golf, Net Cash Positive After Topgolf Stake Sale
Callaway closed a transformational chapter in late 2025, selling Jack Wolfskin for $290 million and a 60% stake in Topgolf at a roughly $1.1 billion valuation, receiving about $800 million in cash and...
- Callaway completed two transformational disposals in 2025: Jack Wolfskin sold for $290 million, and a 60% stake in Topgolf sold at a roughly $1.1 billion valuation.
- Transaction proceeds were about $800 million net, used in part to repay $1 billion of Term Loan B, leaving Callaway in a net cash positive position with roughly $680 million cash and about $480 million of outstanding debt.
- Topgolf is now a discontinued operation for Callaway; Callaway retains a 40% minority stake with no recourse for Topgolf venue financing, leases, or new debt.
- +12 more takeaways
Vistagen Therapeutics FY2026 Q3 Earnings Call - AI-led analysis targets placebo response to steer PALISADE-4
Vistagen used this quarter to close out the randomized portion of PALISADE-3 and double down on understanding why PALISADE-3 showed a higher placebo response than prior studies. Management is running ...
- Completed the randomized portion of PALISADE-3 as previously guided.
- Company is performing cross-study AI/ML analyses to identify covariates and predictors of placebo and drug response across PALISADE studies.
- PALISADE-3 showed a higher placebo response versus PALISADE-2, prompting analytical and operational responses.
- +11 more takeaways
Coincheck Group N.V. Q3 FY2026 Earnings Call - 3iQ Acquisition and CEO Transition Signal Shift to Global Institutional Push
Coincheck reported a stable quarter despite broad crypto price weakness, delivering $915 million in revenue, $9.1 million of Adjusted EBITDA and $2.6 million of net income for Q3 FY2026. Management hi...
- Total revenue was $915 million in Q3 FY2026, up sequentially and up 17% year over year to JPY 143.5 billion, per management commentary.
- Adjusted EBITDA was $9.1 million in Q3, down slightly from $9.5 million in Q2, and down 38% year over year to JPY 1,428 million.
- Net income was $2.6 million for the quarter versus $2.3 million in Q2; the prior-year quarter included large listing and transaction costs that produced a loss.
- +12 more takeaways
Vertex Pharmaceuticals Fourth Quarter 2025 Earnings Call - Povetacicept Emerges as a Potential Renal Franchise Anchor with BLA Rolling and Phase III on Track
Vertex closed 2025 with solid top-line momentum, a diversified commercial mix, and a clear pivot toward building a renal franchise around povetacicept. Financials were strong — $3.2 billion in Q4 and ...
- Q4 2025 revenue was $3.2 billion, up 10% year-over-year; full year 2025 revenue was $12.0 billion, up 9% versus 2024.
- Vertex expects 2026 revenue of $12.95 billion to $13.1 billion, implying 8%–9% growth, and guides for non-CF products to contribute $500 million or more.
- CF remains the cash engine, with full year 2025 CF revenue up 7% globally and the franchise serving over 77,000 patients on Vertex therapies.
- +17 more takeaways
Yelp Q4 2025 Earnings Call - AI and services growth buoy profits as restaurants and retail lag
Yelp closed 2025 with modest top-line growth and stronger profitability, driven by services, data licensing, and a rapid roll out of AI features. Full-year net revenue rose 4% to $1.46 billion, net in...
- Full-year 2025 net revenue was $1.46 billion, up 4% year-over-year, with net income of $146 million, up 10% YoY and diluted EPS of $2.24, up 19% YoY.
- Adjusted EBITDA for 2025 was $369 million, a 25% margin, up 3% year-over-year; 2025 free cash flow was a record $324 million.
- Q4 2025 net revenue fell 1% YoY to $360 million; Q4 net income was $38 million, down 10% YoY; Q4 Adjusted EBITDA was $86 million, down 15% YoY.
- +12 more takeaways
Pinterest Q4 2025 Earnings Call - Record Users, Revenue Lag Tied to Retail Tariffs and Urgent Sales Overhaul
Pinterest closed Q4 2025 with a user base that headline writers will envy, but a revenue beat the company itself called insufficient. The platform reported 619 million MAUs, its tenth straight quarter...
- 619 million MAUs in Q4 2025, up 12% year over year, marking 10 consecutive quarters of record-high users.
- Pinterest reports roughly 80 billion monthly searches, most visual, and 1.7 billion monthly outbound clicks, with over half of searches classified as commercial intent.
- Q4 2025 revenue was $1.319 billion, up 14% year over year (13% constant currency), a result management said fell short of the company’s potential.
- +12 more takeaways
Dexcom Q4 2025 Earnings Call - G7 15-Day rollout lifts margins as Medicare Type 2 non-insulin coverage looms
Dexcom closed 2025 on a healthier note: Q4 revenue rose 13% to $1.26 billion, full-year results beat the high end of guidance, and the company finished with about $2 billion in cash after settling con...
- Q4 2025 revenue $1.26 billion, up 13% year over year; U.S. revenue $892 million, international $368 million (18% growth).
- Full-year revenue finished above the high end of Dexcom's most recent guidance; 2026 revenue guide is $5.16 billion to $5.25 billion, +11% to +13%.
- Gross profit in Q4 was $799.8 million, or 63.5% of revenue, a ~400 basis point improvement year over year and more than 200 basis points sequentially. 2026 gross margin guidance is 63% to 64%, with management targeting 200 to 300 basis points of expansion.
- +12 more takeaways
Bio-Rad Q4 2025 Earnings Call - ddPCR Traction and Supply-Chain Margin Pressures
Bio-Rad closed 2025 with mixed execution. Revenue was essentially flat for the year at $2.583 billion, Q4 sales rose to $693 million driven by diagnostics, while life science remained soft as academic...
- Q4 2025 net sales were $693 million, up 3.9% reported and up 1.7% on a currency neutral basis versus Q4 2024.
- Full year 2025 revenue was $2.583 billion, essentially flat year-over-year on a currency neutral basis.
- Life Science Q4 sales were $268 million, down 2.6% reported and down 4% currency neutral, hurt by weak academic and early-stage biotech instrument demand.
- +13 more takeaways
Applied Materials Q1 FY2026 Earnings Call - AI-Led Ramp Means >20% Semi-Equipment Growth, Clean-Room Capacity Now the Governor
Applied reported a clean beat in Q1 FY2026 with $7.0 billion revenue and $2.38 non-GAAP EPS, then doubled down on a very bullish setup: the company expects its semiconductor equipment business to grow...
- Q1 results: revenue $7.0 billion (upper end of guidance), non-GAAP EPS $2.38, non-GAAP gross margin 49.1% (up 20 bps YoY).
- Company guidance for Q2: revenue $7.65 billion ± $500 million; non-GAAP EPS $2.64 ± $0.20; non-GAAP gross margin ~49.3%; non-GAAP OpEx ~ $1.415 billion.
- Applied expects its semiconductor equipment business to grow more than 20% in calendar 2026, with demand weighted to the second half of the year and momentum expected to carry into 2027.
- +17 more takeaways